Cargando…

Effects of Febuxostat in Early Gout: A Randomized, Double‐Blind, Placebo‐Controlled Study

OBJECTIVE: To assess the effect of treatment with febuxostat versus placebo on joint damage in hyperuricemic subjects with early gout (1 or 2 gout flares). METHODS: In this double‐blind, placebo‐controlled study, 314 subjects with hyperuricemia (serum uric acid [UA] level of ≥7.0 mg/dl) and early go...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalbeth, Nicola, Saag, Kenneth G., Palmer, William E., Choi, Hyon K., Hunt, Barbara, MacDonald, Patricia A., Thienel, Ulrich, Gunawardhana, Lhanoo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Gout
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725733/ https://www.ncbi.nlm.nih.gov/pubmed/28975718 http://dx.doi.org/10.1002/art.40233

Ejemplares similares

Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo‐Controlled Study
por: Saag, Kenneth G., et al.
Publicado: (2018)

Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial
por: Saag, Kenneth G., et al.
Publicado: (2022)

Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Superiority of Low‐Dose Benzbromarone to Low‐Dose Febuxostat in a Prospective, Randomized Comparative Effectiveness Trial in Gout Patients With Renal Uric Acid Underexcretion
por: Yan, Fei, et al.
Publicado: (2022)

A Randomized, Double‐Blind, Active‐ and Placebo‐Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout
por: Poiley, Jeffrey, et al.
Publicado: (2016)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
por: Botson, John K., et al.
Publicado: (2022)

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study
por: Gunawardhana, Lhanoo, et al.
Publicado: (2018)

Brief Report: Monosodium Urate Monohydrate Crystal Deposits Are Common in Asymptomatic Sons of Patients With Gout: The Sons of Gout Study
por: Abhishek, Abhishek, et al.
Publicado: (2018)

Development and First Validation of a Disease Activity Score for Gout
por: Scirè, Carlo A., et al.
Publicado: (2016)

Computational Lexical Analysis of the Language Commonly Used to Describe Gout
por: Lawrence Edwards, N., et al.
Publicado: (2016)

Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo‐Controlled Study
por: Gunawardhana, Lhanoo, et al.
Publicado: (2017)

The Impact of Label Changes (Boxed Warning) on Real-World Febuxostat Utilization in Patients with Gout: A Cross-Sectional Drug Utilization Study
por: Sosinsky, Alexandra Z., et al.
Publicado: (2023)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout
por: Gaffo, Angelo L, et al.
Publicado: (2010)

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
por: Jackson, Robert L, et al.
Publicado: (2012)

African American patients with gout: efficacy and safety of febuxostat vs allopurinol
por: Wells, Alvin F, et al.
Publicado: (2012)

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
por: Becker, Michael A, et al.
Publicado: (2010)

Management of hyperuricemia in gout: focus on febuxostat
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study
por: Dalbeth, Nicola, et al.
Publicado: (2019)

A Randomized, Double-Blind, Non-Inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects With or Without Gout
por: Zhang, Fengchun, et al.
Publicado: (2019)

Epidemiology, risk factors, and lifestyle modifications for gout
por: Saag, Kenneth G, et al.
Publicado: (2006)

Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout
por: Kamel, Bishoy, et al.
Publicado: (2022)

Comment on “A Randomized, Double-Blind, Non-inferiority Study of Febuxostat Versus Allopurinol in Hyperuricemic Chinese Subjects with or Without Gout”
por: van Leeuwen, Kevin D. B., et al.
Publicado: (2019)

Febuxostat in the management of hyperuricemia and chronic gout: a review
por: Hu, Miao, et al.
Publicado: (2008)

Febuxostat: A Novel Agent for Management of Hyperuricemia in Gout
por: Bisht, Manisha, et al.
Publicado: (2011)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Racial and Sex Disparities in Gout Prevalence Among US Adults
por: McCormick, Natalie, et al.
Publicado: (2022)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

When underlying biology threatens the randomization principle — initial gout flares of urate-lowering therapy
por: Choi, Hyon K., et al.
Publicado: (2022)

Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis
por: Kim, Sang-Hyon, et al.
Publicado: (2020)

Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
por: Cheng, Ching-Lan, et al.
Publicado: (2022)

A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
por: Lee, Joondon, et al.
Publicado: (2023)

Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes
por: Wei, Jie, et al.
Publicado: (2023)

Gout. Imaging of gout: findings and utility
por: Perez-Ruiz, Fernando, et al.
Publicado: (2009)

Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient
por: Frassetto, Lynda Ann, et al.
Publicado: (2016)

Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat
por: Sheer, Richard, et al.
Publicado: (2017)

Clinical study of different doses of atorvastatin combined with febuxostat in patients with gout and carotid atherosclerosis
por: Zhang, Zheng, et al.
Publicado: (2020)

The efficacy and tolerability of febuxostat treatment in a cohort of Chinese Han population with history of gout
por: Huang, Yuan-Yuan, et al.
Publicado: (2020)

Cost-effectiveness of allopurinol versus febuxostat in the treatment of gout patients: A systematic review
por: Rezapour, Aziz, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0m33avakhd0p0u14v3ma4g9dq9